Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection

Jessica R. Spengler, Centers for Disease Control and Prevention
M Kelly Keating, Centers for Disease Control and Prevention
Anita McElroy, Emory University
Marko Zivcic, Centers for Disease Control and Prevention
JoAnn D Coleman-McCray, Centers for Disease Control and Prevention
Jessica R. Harmon, Centers for Disease Control and Prevention
Brigid C. Bollweg, Centers for Disease Control and Prevention
Cynthia S Goldsmith, Centers for Disease Control and Prevention
Eric Bergeron, Centers for Disease Control and Prevention
James G. Keck, The Jackson Laboratory

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Infectious Diseases
Volume: Volume 216, Number 11
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option C | 2017-12-01, Pages 1386-1397
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/infdis/jix215
Permanent URL: https://pid.emory.edu/ark:/25593/tvfpn

Final published version: http://dx.doi.org/10.1093/infdis/jix215

Copyright information:
Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. This is an Open Access work distributed under the terms of the Creative Commons Universal : Public Domain Dedication License (http://creativecommons.org/publicdomain/zero/1.0/).

Accessed December 16, 2019 10:34 AM EST
Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection

Jessica R. Spengler,1 M. Kelly Keating,2 Anita K. McElroy,1,3 Marko Zivcic,1 JoAnn D. Coleman-McCray,1 Jessica R. Harmon,1 Brigid C. Bollweg,2 Cynthia S. Goldsmith,2 Eric Bergeron,1 James G. Keck,4 Sherif R. Zaki,2 Stuart T. Nichol,4 and Christina F. Spiropoulou1

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhagic disease seen exclusively in humans. Central nervous system (CNS) infection and neurological involvement have also been reported in CCHF. In the current study, we inoculated NSG-SGM3 mice engrafted with human hematopoietic CD34+ stem cells with low-passage CCHF virus strains isolated from human patients. In humanized mice, lethal disease develops, characterized by histopathological change in the liver and brain. To date, targets of neurological infection and disease have not been investigated in CCHF. CNS disease in humanized mice was characterized by gliosis, meningitis, and meningoencephalitis, and glial cells were identified as principal targets of infection. Humanized mice represent a novel lethal model for studies of CCHF countermeasures, and CCHF-associated CNS disease. Our data suggest a role for astrocyte dysfunction in neurological disease and identify key regions of infection in the CNS for future investigations of CCHF.

Keywords. Crimean-Congo hemorrhagic fever; NSG-SGM3 humanized mice; neuropathology; glial cell; meningitis.

Tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV; genus Nairovirus; family Bunyaviridae) is the etiologic agent of Crimean-Congo hemorrhagic fever (CCHF). Disease can vary from mild, nonspecific febrile illness to severe hemorrhagic clinical signs. Neurological involvement in CCHF was also described in the seminal report on the 1944 outbreak in Soviet troops in the Crimean peninsula, in which general cerebral, meningial, and slight psychological and neurological symptoms were noted as the most characteristic clinical features in these cases [1]. Based on these findings and degeneration of the autonomic nervous system observed in later cases, CCHFV was considered by early researchers to be a neurotropic virus [2].

Further descriptions of CCHF neurological involvement and disease include a pediatric patient who presented with abnormal behavior (violent reactions, extreme agitation, and incoherent speech) and later exhibited vestibular signs [2], virus isolation from the hypothalamus in a fatal case [3], inflammatory infiltrates in the cerebrum [4], acute encephalopathy associated with subdural hematoma [5], and a fatal brain herniation [6]. Despite these findings and reports of other

Nairovirus-associated neurological disease [7, 8], the incidence, pathogenesis, and clinical outcome of central nervous system (CNS) infection in patients with CCHF has not been investigated. In addition, in vivo model studies are limited by the absence of overt disease in animals, including nonhuman primates. Current animal models are restricted to signal transducer and activator of transcription 1 knockout (STAT-1−/−) and interferon α/β-receptor knockout (IFNAR−/−) mice, deficient in essential innate immune pathways [9–11].

In this article, we describe a novel lethal disease model of CCHF in humanized mice. Hu-NSG-SGM3 mice, derived from NSG-SGM3 (NOD.Cg-Prkdacid Il2rgtm1Wjl Tg [CMV-IL3, CSF2, KITLG] 1Eav/MloySzJ) mice, are irradiated and intravenously injected with human CD34+ hematopoietic stem cells. We infected SGM3 humanized mice with 2 strains of CCHFV isolated from human patients in Oman (CCHFV-OM) or Turkey (CCHFV-TR). All mice infected with CCHFV-TR developed progressive disease, with high levels of viral antigen in the liver, spleen, and brain. In mice that succumbed to disease, the highest level of virus, detected with quantitative reverse-transcription polymerase chain reaction (qRT-PCR), immunohistochemistry, and electron microscopy, was in the brain. In contrast, all mice infected with CCHFV-OM exhibited mild clinical signs and recovered; viral antigen was uniformly absent in the brains of these mice. Viral antigen was primarily detected in glial cells, including astrocytes and microglia, and in the meninges. These findings indicate that neuropathology, which included gliosis and meningitis/meningoencephalitis, is a key component of disease in this model. In addition to providing a lethal model...
for therapeutic studies, humanized mice can be used for further investigations of CCHF-associated neuropathogenesis in vivo.

MATERIALS AND METHODS

Ethics Statement
All animal procedures were approved by the Institutional Animal Care and Use Committee (2736SPEMOUUC) of the Centers for Disease Control and Prevention (CDC) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals [12]. The CDC is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Procedures conducted with CCHFV or CCHFV-infected animals were performed in the CDC biosafety level 4 laboratory.

Humanized Mice
One donor cohort of 21 female Hu-NSG™-SGM3 mice (stock No. 701362) was obtained from Jackson Laboratories. Mice were evenly distributed in experimental groups based on the percentage of human CD45⁺ cells in peripheral blood as determined with flow cytometry 12 weeks after engraftment. Mice were housed in a climate-controlled laboratory with a 12-hour day/12-hour night cycle, provided sterilized commercially available mouse chow and water ad libitum, and group housed with sterile bedding in an isolator caging system. Mice were humanely euthanized when clinical illness scores—based on neurological signs, changes in mentation, ataxia, dehydration, dyspnea, and/or weight loss (>20%)—indicated that the animal was in distress or in the terminal stages of disease.

Virus Inoculation
SGM3 humanized mice (16 weeks after engraftment) were sham-injected with sterile Dulbecco’s modified Eagle’s medium or inoculated intraperitoneally with 10⁶ median tissue culture infective dose (TCID₅₀) of CCHFV Oman-199809166 (GenBank accession nos. KY362516, KY362518, and KY362514) or CCHFV Turkey-200406546 (CCHFV-TR; GenBank accession nos. KY362517, KY362519, KY362515). Both viruses were isolated from hospitalized human patients with unknown clinical outcomes. CCHFV-OM virus stock was passaged twice in Vero E6 cells and once in SW13 cells, and CCHFV-TR was passaged once in suckling mouse brain and once in SW13 cells. Inoculum titers were calculated using a method based on that of Reed and Muench [13], on SW13 cells fixed and stained with crystal violet 6 days after infection.

qRT-PCR Methods
RNA was extracted from blood and homogenized tissue samples using the MagMAX-96 Total RNA Isolation Kit (Thermo Fisher Scientific) on a 96-well ABI MagMAX extraction platform with a DNaseI treatment step, according to the manufacturer’s instructions. RNA was quantitated using a 1-step real-time RT-PCR targeting a strain-specific nucleoprotein gene sequence, and it was standardized to 18S with a SuperScript III Platinum One-Step qRT-PCR Kit (Thermo Fisher Scientific), according to the manufacturer’s instructions (primer and probe sequences available on request). TCID₅₀ equivalents were determined by analyzing, in parallel, standard dilutions of RNA extracted from the virus stock vial used for inoculations.

Flow Cytometry
Cell suspensions were prepared from macerated liver and spleen tissues; 2 × 10⁶ of the spleen cells and all of the liver mononuclear cells obtained from gradient selection on Histopaque 1077 (Sigma-Aldrich) were used for subsequent flow cytometric staining. Cells were stained with LIVE/DEAD Fixable Near-IR stain (1:500) in phosphate-buffered saline, washed in flow buffer (phosphate-buffered saline, 2% fetal bovine serum) and then treated with Fc blocking reagent (Miltenyi Biotec). Surface stains were added directly to cells, and after 2 washes in flow buffer, cells were treated with Fix/Perm and then washed twice in Perm/Wash buffer (both from BD). Intracellular staining was done for perforin-PCP-Cy5.5 (delta G9; BD), followed by 2 washes in Perm/Wash buffer before data were acquired on a Stratagene cytomter. Data were analyzed using FlowJo software, version 10 (Tree Star). Three of the 5 CCHFV-TR mice with terminal-stage disease were excluded because flow cytometry could not be performed in real time on the day of euthanasia. One mouse was excluded from flow cytometric analyses owing to low engraftment (mouse OM-7; 12% CD45⁺ cells in liver and spleen). For additional details on tissue processing, cell staining, and antibody panels see Supplementary Methods.

Histochemical Staining, Immunohistochemistry, and Electron Microscopy
Tissue specimens were fixed in 10% neutral buffered formalin and subjected to gamma irradiation (2 × 10⁶ rad). Tissues were routinely processed for paraffin embedding, sectioning and staining with hematoxylin-eosin, and select samples were stained with Prussian blue for detection of iron. For immunohistochemical assays, slides were stained with a rabbit polyclonal antibody reactive to CCHFV N protein (IBT Bioservices) diluted 1:1000 and/or glial fibrillary acidic protein 6F2 (Agilent Technologies) diluted 1:200. On-slide embedding and transmission electron microscopy were performed as described elsewhere [14]. Areas were selected that, in a serial light microscopic section, had shown intense anti-CCHFV immunoreactivity. For additional details on slide processing, see Supplementary Methods.

RESULTS

CCHFV Replication and Dissemination in SGM3 Humanized Mice
SGM3 humanized mice were inoculated intraperitoneally with 10⁴ TCID₅₀ of CCHFV-OM (n = 9) or CCHFV-TR (n = 8) strains. Three mice per group, and a control, were euthanized 4 days after infection to assess clinical chemistry findings (Supplementary Figure S1), and viral replication early in
infection. The other animals were followed up clinically and sampled as described above, after euthanasia due to disease or at study completion (33 days after infection). Animals inoculated with CCHFV-OM (n = 6) exhibited minimal weight loss and recovered (maximum median loss at 2 days after infection, 4.99% ± 4.47% SD; maximum absolute loss at 3 days after infection, 16.7%; Figure 1A). In contrast, animals inoculated with CCHFV-TR (n = 5) displayed slow progressive weight loss, ultimately requiring euthanasia at 13, 20, or 23 days after infection (Figure 1B). Viral RNA levels were determined by qRT-PCR in blood and tissues of CCHFV-inoculated SGM3 humanized mice (Figure 1C).

At 4 days after infection, viral RNA was detected in all blood and tissue samples analyzed from mice infected with CCHFV-OM.
Figure 2. Characterization of human CD45+ cell reconstitution, T-cell activation, and CD8+ T-cell perforin expression in liver and spleen tissue from SGM3 humanized mice infected with Crimean-Congo hemorrhagic fever virus (CCHFV). A, Quantitation of human CD45+ cells in liver and spleen demonstrates decreased lymphocyte populations at late time points in infected animals, independent of viral strain or presence of disease. Both CD4+ and CD8+ T cells were found to be activated in mice infected with CCHFV, at early and late time points, independent of viral strain or presence of disease. CCHFV-OM and TR, CCHFV isolated from human patients in Oman and Turkey, respectively; DMEM, Dulbecco’s modified Eagle’s medium; 4 d, 4 days after infection. B, Flow cytometric analysis of perforin expression in liver and spleen samples from mock and CCHFV-infected SGM3 humanized mice. Data are presented as percentage of HLA-DR/CD38+ T cells expressing perforin (with standard deviation), and representative contour plots demonstrate shift in expression observed in mice with terminal-stage disease infected with a CCHFV-TR (red) compared with control mice sham-infected with DMEM (blue).
either CCHFV-OM or CCHFV-TR. High levels of viral RNA were detected in the brains of CCHFV-TR–infected animals that succumbed to disease, up to 2 logs higher than levels in CCHFV-OM animals at study completion. Ocular involvement is reported in other neurotropic viral infections. Thus, after virus was detected at high levels in brains of mice that succumbed to disease at 13 days after infection, ocular samples were collected for PCR analyses in the remaining mice (TR-5 and TR-6, n = 2; OM-4 through OM-9, n = 6); viral RNA was detected in all ocular samples from CCHFV-inoculated mice, regardless of strain.

**CD45⁺ Depletion and Differential T-Cell Activity and Function in CCHFV-Infected Humanized Mice**

SGM3 humanized mice support high levels of human CD45⁺ cell reconstitution, which may contribute to the immune response to viral infections [15–17]. hCD45⁺ reconstitution levels were similar at 4 days after infection in mock-inoculated control mice and infected mice regardless of challenge virus (>60% engraftment; Figure 2A). However, in infected mice that were euthanized, either because of disease or at the scheduled end of the experiment, hCD45⁺ levels were significantly lower than in controls, regardless of virus strain. This may represent apoptosis or direct infection of these cells by CCHFV or may be due to cellular localization to sites that were not sampled.

Both phenotypic activation on T cells and cytotoxic functional activity were assessed in the mice. Up-regulation of HLA-DR and CD38, markers of human T-cell activation [18, 19], was observed in all humanized mice infected with CCHFV, regardless of strain, sample time point, or disease outcome (Figure 2A). The early activation marker CD69 was also examined but was not notably elevated at any time point on either CD4⁺ or CD8⁺ T cells in infected mice compared with control mice (Supplementary

**Figure 3.** Extraneural histological analysis of humanized mice infected with Crimean-Congo hemorrhagic fever virus (CCHFV). Pulmonary, hepatic, and splenic findings described in control mice, including the presence of mixed inflammatory infiltrate, were also noted in CCHFV-infected humanized mice and considered secondary to factors outside the experimental viral infection. A, In contrast to control mice, an increase in individual hepatocellular death was observed both within the inflammatory foci (yellow arrows) and randomly throughout the parenchyma (white arrows). Vascular degeneration, indicating hepatocellular damage, was also noted in some animals (blue arrow). B, In the liver, with use of an anti-CCHFV antibody, immunoreactivity was seen in histiocytes and multinucleated giant macrophages within hepatic inflammatory foci (left image), Kupffer cells (black arrow), and rare hepatocytes (white arrow). C, D, Rare staining was also noted within mononuclear cells in the lung (C) and in mesenchymal connective tissue that remained adherent to organs when sampled at necropsy, such as perirenal adipose (D).
Figure 3C). Of note, elevated levels of perforin, a marker of cyto-
toxic functional activity, were observed in the CD8+ T cells of the
mice that had to be euthanized after CCHFV-TR infection
(Figure 2B). It is unclear whether this represents a population of
CD8+ T cells that could manage to nonspecifically kill infected
cells in these animals or a population of CD8+ T cells that were
contributing to immune-mediated disease.

**Histological and Immunohistochemical Evaluation of Extraneural Tissues in CCHFV-Infected SGM3 Humanized Mice**

Hepatic cellular infiltrates, in both CCHFV-OM- and CCHFV-TR-infected humanized mice, were largely consistent with control humanized mice (Supplementary Figure S3); cell-
lar infiltrates were mild to moderate in all but 1 animal (TR-
1), in which infiltrates were abundant. However, in all evaluated
CCHFV-TR mice and in OM-9, individual cell death was more
frequent and both present within inflammatory foci and ran-
domly distributed throughout the parenchyma (Figure 3A). In
addition, vacuolar degeneration was noted in some animals,
as well as a mild ductular reaction. In contrast, the remaining
CCHFV-OM mice exhibited only rare, single-cell hepatocyte
death associated with the inflammatory foci, similar to the con-
trol mice. Histopathological changes in lungs and spleens of
infected humanized mice were consistent with those observed
in control mice. Other tissues examined, including heart, eye,
kidney, adrenal gland, and ovary/uterus, revealed no significant
findings.

Immunohistochemistry for CCHFV showed staining in the liver,
spleen, lungs, and adrenal glands (Table 1). In the liver,
strong cytoplasmic immunoreactivity was noted primarily
in histiocytes and multinucleated giant macrophages within
inflammatory foci; sinusoidal lining cells, including Kupffer
cells and endothelial cells; and in rare hepatocytes (Figure 3B).
Immunoreactivity was noted within rare mononuclear cells
consistent with histiocytes in the splenic white pulp (consist-
ent with dendritic cells) and in perivascular inflammatory foci
within the lungs (Figure 3C). Small numbers of mesenchymal
cells in connective and adipose tissues that were adherent to
organs were immunoreactive, including tissues surrounding
organs in which immunostaining was not observed (kidney,
eye, heart; Figure 3D), which may explain viral RNA detection
by PCR in organs that were negative by immunohistochemistry.
Finally, rare spindle cells consistent with endothelial cells had
cytoplasmic staining in the adrenal gland of 2 animals (TR-4
and TR-6 at 20 and 23 days after infection, respectively).

**Severe Neurological Disease in CCHFV-TR-Infected SGM3 Humanized Mice**

Severe neurological disease and positive immunostaining
for CCHFV were noted in the CCHFV-TR mice that were

<table>
<thead>
<tr>
<th>Animal Designation</th>
<th>Time After Infection, d</th>
<th>Brain</th>
<th>Liver</th>
<th>Spleen</th>
<th>Lung</th>
<th>Ovary</th>
<th>Uterus</th>
<th>Kidney</th>
<th>Adrenal</th>
<th>Eye</th>
<th>Heart</th>
<th>GI Tract</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMEM-1</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>DMEM-2</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>DMEM-3</td>
<td>33</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>DMEM-4</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TR-1</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TR-2</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TR-3</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TR-1&lt;sup&gt;4h&lt;/sup&gt;</td>
<td>20</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TR-5&lt;sup&gt;5h&lt;/sup&gt;</td>
<td>23</td>
<td>+++</td>
<td>+</td>
<td>NS</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TR-6&lt;sup&gt;5h&lt;/sup&gt;</td>
<td>23</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TR-7&lt;sup&gt;6h&lt;/sup&gt;</td>
<td>13</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TR-8&lt;sup&gt;6h&lt;/sup&gt;</td>
<td>13</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-1</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>OM-2</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>OM-3</td>
<td>4</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>OM-4</td>
<td>33</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-5</td>
<td>33</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-6</td>
<td>33</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-7</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-8</td>
<td>33</td>
<td>–</td>
<td>+</td>
<td>NS</td>
<td>+</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>OM-9</td>
<td>33</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>NS</td>
<td>–</td>
<td>–</td>
<td>NS</td>
<td>NS</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: –, negative results at staining; +, mild immunostaining; ++, moderate immunostaining; ++++, abundant immunostaining; CCHFV, Crimean-Congo hemorrhagic fever virus; DMEM, Dulbecco's modified Eagle's medium; GI, gastrointestinal; NS, not sampled (ie, samples not obtained and/or not evaluated with immunohistochemistry).

*Abbreviations: Tissues from SGM3 humanized mice inoculated with CCHFV isolated from a human patient in Turkey (CCHFV-TR) or Oman (CCHFV-OM) and euthanized at the indicated day after infection were stained with anti-CCHFV antibodies to detect the virus. Viral antigen was localized to brain, hepatic, splenic, and pulmonary tissues, with adrenal staining seen in a subset of CCHFV-TR mice. Antigen was most abundant in CCHFV-TR–inoculated mice euthanized because of disease.

*Euthanized because of disease.
euthanized owing to progressive weight loss at 13, 20, and 23 days after infection (Figure 4); no remarkable histological changes or anti-CCHFV immunohistochemistry immunoreactivity were seen in any CCHFV-inoculated mice euthanized at 4 days after infection, or in any CCHFV-OM survivors.

In CCHFV-TR mice with terminal-stage disease, patchy, mild to moderate expansion of the meninges by mixed but predominately mononuclear inflammatory cells composed of lymphocytes, including rare CD8$^+$ lymphocytes, histiocytes, plasma cells, and some neutrophils with immature band and ring forms, was observed (Figure 4A). In severe cases, small numbers of cells extended into the subjacent cortical parenchyma and were associated with edema and vascular congestion with increased leukocytes. Two animals had multiple loose aggregates of activated glial cells and microglia, resident macrophage cells in the brain, consistent with early glial nodules both within the cerebrum and cerebellum (Figure 4B). By thin-section electron microscopy, a virus particle with morphologically consistent with a bunyavirus was found in brain parenchyma directly below the meninges (Figure 4C).

Mild to extensive anti-CCHFV immunostaining was seen throughout the brains of CCHFV-TR humanized mice with terminal-stage disease, though comprehensive evaluation of all regions from every brain was not possible due to the nature of the samples. Immunostaining corresponded to regions of pathological changes observed with hematoxylin-eosin evaluation, and the most common pattern seen was abundant immunostaining in areas of menigitis/meningoencephalitis and within reactive astrocytes in areas of gliosis, with extension of immunostaining into the subpial food processes (Figure 5A). In 1 animal (TR-4, at 20 days after infection), multiple astrocytic foci were present in the cerebellar cortex, with cell bodies within the Purkinje layer, consistent with Bergmann glial cells (Figure 6A and 6B). In addition, widely dispersed rare immunostaining of glial cells and neurons was also present without notable neuropathological changes. This included both single glial and neuronal cells, and clusters of neurons localized to specific nuclei, such as the habenular nucleus (Figure 5A). Confirmation of these cells as astrocytes or neurons was accomplished by double staining against CCHFV and glial fibrillary acidic protein (Figures 5B, 5C, 6C, and 6D), and by cellular morphology.

**DISCUSSION**

Pathogenesis studies of CCHF in animal models are limited because most vertebrate species other than humans, although susceptible to CCHFV infection [20], do not show signs of disease [21]. Even nonhuman primates, the reference standard animal model for other highly pathogenic hemorrhagic fever viruses that cause disease predominantly restricted to humans (eg, Ebola and Marburg viruses [22]), appear to be largely refractory to CCHF disease [23–26]. In this article, we describe a new lethal mouse model of CCHF, in SGM3 humanized mice, characterized by neurological disease and several liver histopathological features comparable to those in human cases, including vacuolar degeneration/steatosis, increased single-cell necrosis, and distribution of viral antigen within Kupffer cells, endothelial cells, and hepatocytes [27, 28].

In wild-type mice inoculated with CCHFV, viremia is either absent or mild and transient, and low levels of viral RNA are detected in an array of tissues without any clinical signs [9–11]. Virus is widely disseminated in humanized mice, similar to findings in IFNAR$^{-/-}$ and STAT-1$^{-/-}$ mice. However, the time from exposure until euthanasia criteria are met is more prolonged.
than in existing immunodeficient mouse models of CCHF, and thus more consistent with the time course seen in fatal human cases (incubation of 1–13 days, and death generally after 5–14 days) [29]. Viral RNA was detected in the brains of humanized mice at 4 days after infection, increased over time, and had its highest levels in the brains of mice that succumbed to disease. In contrast, CCHFV is detected in the brains of IFNAR-/- and STAT-1-/- mice, but at lower levels than in other tissues (eg, liver and spleen) [9, 11]. This difference is probably due to the length of the clinical course in each model; the rapid, acute nature of disease in IFNAR-/- and STAT-1-/- mice (< 7 days) may prohibit high levels of viral dissemination into the brain, as seen in other models of viral infection when disease course is abbreviated rather than prolonged (eg, Nipah virus) [30].

In humanized mice, abundant CNS anti-CCHFV immunostaining was seen in the meninges and glia limitans, and in some regions submeningeal vessels were prominent, congested, and associated with parenchymal edema, indicators of vascular leakage. Endothelial damage is believed to be a central pathological mechanism in CCHF; increased levels of markers for

Figure 5. Infection of glial cells and neurons in humanized mice with terminal-stage disease infected with a Crimean-Congo hemorrhagic fever virus strain isolated from a human patient in Turkey (CCHFV-TR). Abundant anti-CCHFV immunostaining in glial cells and rare focal immunoreactivity in neurons were observed. A, Transverse section through the brain of a CCHFV-TR–infected mouse shows multiple foci of immunostaining for CCHF. Intense staining of neurons from the habenular nucleus is noted (red box). Immunostaining of the meninges and reactive astrocytes (arrows in black box) is seen in the hypothalamus. Strong, diffuse cytoplasmic immunoreactivity is seen in a reactive astrocyte (green box). B, Astrocytes show colocalization of glial fibrillary acidic protein (GFAP; brown) and CCHFV (red). C, Neurons with strong cytoplasmic immunoreactivity for CCHFV (red, yellow arrows) are surrounded by astrocytes and astrocytic cell processes that are immunoreactive with GFAP staining (brown).
endothelial and vascular damage, and plasma leakage are positively association with severity of disease [31]. As described in human cases, we detected CCHFV antigen in endothelial cells of several organs, including the liver and adrenal gland. These findings, including viral tropism for endothelial cells and histopathological evidence of vascular leakage in the brain, along with previous reports of vascular compromise, support hematogenous entry of CCHFV through a compromised blood-brain barrier (BBB) at the level of the brain microvessel endothelium.

Given the propensity for glial cell infection in the brains of the SGM3 humanized mice, CCHFV entry is probably enhanced by activation of astrocytes and impairment of their contribution to barrier function. Foot processes from astrocytes form a complex network surrounding the capillaries, and this close cell association is important in induction and maintenance of the barrier properties [32]. Glial cells form a structural framework to support neuronal cells and play a role in preventing pathogen entry into the brain. Morphological and functional BBB characteristics depend on the CNS environment and on the contribution of perivascular astrocytes [33, 34]. Furthermore, an astrocyte-mediated bystander effect has been described with other encephalitic viruses, in which infected astrocytes in an endothelial cell coculture model increased permeability of the endothelium, causing endothelial cell apoptosis, morphology altered astrocytes, and gap junction–dependent disruptions in signaling between uninfected and infected cells [35]. Altogether, infection of glial cells and astrocytes provides a mechanism of disease consistent with reports of increased permeability in brain membranes of patients [2, 5].

The neurological involvement described in CCHF case reports may be primarily due to cytokine-mediated endothelial barrier dysfunction, or may be a direct effect of the virus in the brain [6]. Astrocytes may also play a role in disrupting CNS barriers in response to T-cell activation. CD8+ T-cell activation of astrocytes is a well-described mechanism of BBB disruption [36, 37]. We were able to detect only rare human CD8+ T cells in the brains of these mice by immunohistochemistry; however, it is unclear whether their presence, although in low numbers, directly contributes to alterations in CNS barriers or is secondary to disruption permitting cellular infiltration. Determining the role of these cells and characterizing CCHFV-mediated immune stimulation in the brain warrant future investigations.

We identified focal areas of immunoreactivity in the region of the habenular nuclei and in the hypothalamus (Figure 5A). Both of these regions are parts of the limbic system, a set of
brain structures that mediate a variety of emotional and motivational processes [38]. Infection of these regions is described in other neurotropic viral infections, including neurotropic influenza and a neurotropic murine coronavirus [39, 40]. Of particular interest is the hypothalamus because CCHFV has been isolated from the patient’s hypothalamus in a fatal case [3]. In SGM3 humanized mice, we observed abundant CCHFV immunostaining of the hypothalamic meninges, and astrocytes in the presence of meningitis and reactive astrogliosis. The infection of these regions, seen in both human patients and humanized mice, suggests that future investigations should evaluate acute and long-term physiologic regulatory function and behavioral abnormalities in CCHF.

It is not unprecedented for a viral disease with overt hemorrhagic signs to also affect the brain. Lassa virus, Junin virus, and other hemorrhagic arenaviruses enter the brain and cause neurological symptoms that can include encephalitis, hearing loss, and tremors [41, 42]. Similar to our observations in CCHFV brain infection of SGM3 humanized mice, Junin virus also infects astrocytes, and neurodegenerative reactive astrogliosis may play a role in the pathogenesis of acute and late neurological symptoms in Junin virus infection [43–46]. Furthermore, many closely related bunyaviruses, including those of the California serogroup (genus Orthobunyavirus) and Rift Valley fever virus (genus Phlebovirus) are well characterized as causing neurological symptoms in human disease, supporting the potential for more frequent neurological involvement in CCHF than currently recognized.

Findings in recent cases and animal model studies of Ebola virus disease [47, 48] emphasize the need to consider viral dissemination to immune-privileged sites, such as the brain, even in viral disease not initially thought to have CNS involvement. CCHFV has demonstrated neurotropism in severe disease [3], but to our knowledge there have been no detailed investigations of CNS infection. Neither of the 2 reports of histopathological findings in human CCHF cases included findings in nervous tissue [27, 49], and CCHF research has been limited to severely immunocompromised mouse strains that develop rapid, acute disease prohibiting dissemination to the CNS. Although limitations remain in the use of humanized mouse models, these models have been instrumental in studies of human-specific viruses, bacteria, and parasites [50].

In this article, we present a novel humanized mouse model of CCHF, describing cellular targets and focal regions of infection in the brain. Our studies form a basis for more comprehensive research on (1) mechanisms of viral entry into the CNS, (2) neuroanatomical targets of infection, (3) viral persistence in the CNS, and (4) incidence of neurological signs and sequelae in human CCHF. Answers to these questions will be instrumental in determining the public health impact of CNS infection by CCHFV, guiding appropriate clinical care for patients, and developing targeted medical countermeasures.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

**Acknowledgments.** We thank Pierre Rollin for initial strain isolation studies, Lisa Guerrero and César Albariño for assistance with next generation sequencing, Silvia Sisó for neuropathology consultation, Tim Flietstra for guidance on statistical analyses, Tatyana Klimova for assistance with editing the manuscript, Stephen Welch and Joy Gary for assistance with figures, Jonathan Towner for critical review, and members of the CDC’s Comparative Medicine Branch for providing care for the animals.

**Financial support.** This work was partially supported by an appointment to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC, by the National Institutes of Health (loan repayment award to J. R. S.), and by a CDC foundation project funded by the National Institute of Allergy and Infectious Diseases (grant R01AI109008 to E. B.).

**Potential conflicts of interest:** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

References


